Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis

Science Translational Medicine

Volumn 4, Issue 146, 2012, Pages

  Flögel, Ulrich ^a   Burghoff, Sandra ^a   Van Lent, Peter L E M ^b   Temme, Sebastian ^a   Galbarz, Lisa ^a   Ding, Zhaoping ^a   El Tayeb, Ali ^c   Huels, Sandra ^a   Bönner, Florian ^a   Borg, Nadine ^a   Jacoby, Christoph ^a   Müller, Christa E ^c   Van Den Berg, Wim B ^b   Schrader, Jürgen ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (CYCLOHEXYLETHYLTHIO)ADENOSINE; 2 (CYCLOHEXYLETHYLTHIO)ADENOSINE 5' MONOPHOSPHATE; 5' NUCLEOTIDASE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISTRADEFYLLINE; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME PRODRUG THERAPY; FLUORINE NUCLEAR MAGNETIC RESONANCE; HISTOLOGY; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; VASODILATATION;

5'-NUCLEOTIDASE; ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; ARTHRITIS, RHEUMATOID; INFLAMMATION; JOINTS; MALE; MICE; PRODRUGS; RECEPTOR, ADENOSINE A2A;

EID: 84864881916     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003717     Document Type: Article

References (48)

1. E. D. Harris Jr., Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322, 1277-1289 (1990).
2. W. B. van den Berg, Animal models of arthritis. What have we learned? J. Rheumatol. Suppl. 72, 7-9 (2005).
3. T. Takeuchi, Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J. Med. 60, 75-81 (2011).
4. J. C. Shryock, L. Belardinelli, Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. Am. J. Cardiol. 79, 2 -10 (1997).
5. H. K. Eltzschig, T. Eckle, A. Mager, N. Küper, C. Karcher, T. Weissmüller, K. Boengler, R. Schulz, S. C. Robson, S. P. Colgan, ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ. Res. 99, 1100-1108 (2006).
6. C. W. Wong, T. Christen, I. Roth, C. E. Chadjichristos, J. P. Derouette, B. F. Foglia, M. Chanson, D. A. Goodenough, B. R. Kwak, Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat. Med. 12, 950-954 (2006).
7. U. Schenk, A. M. Westendorf, E. Radaelli, A. Casati, M. Ferro, M. Fumagalli, C. Verderio, J. Buer, E. Scanziani, F. Grassi, Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal. 1, ra6 (2008).
8. S. Deaglio, S. C. Robson, Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 61, 301-332 (2011).
9. J. Reutershan, I. Vollmer, S. Stark, R. Wagner, K. C. Ngamsri, H. K. Eltzschig, Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 23, 473-482 (2009).
10. M. Takedachi, D. Qu, Y. Ebisuno, H. Oohara, M. L. Joachims, S. T. McGee, E. Maeda, R. P. McEver, T. Tanaka, M. Miyasaka, S. Murakami, T. Krahn, M. R. Blackburn, L. F. Thompson, CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J. Immunol. 180, 6288-6296 (2008).
11. P. Koszalka, B. Ozüyaman, Y. Huo, A. Zernecke, U. Flögel, N. Braun, A. Buchheiser, U. K. Decking, M. L. Smith, J. Sévigny, A. Gear, A. A. Weber, A. Molojavyi, Z. Ding, C. Weber, K. Ley, H. Zimmermann, A. Gödecke, J. Schrader, Targeted disruption of cd73/ecto-5?-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 95, 814-821 (2004).
12. A. Zernecke, K. Bidzhekov, B. Ozüyaman, L. Fraemohs, E. A. Liehn, J. M. Lüscher-Firzlaff, B. Luscher, J. Schrader, C. Weber, CD73/ecto-5 ? -nucleotidase protects against vascular inflammation and neointima formation. Circulation 113, 2120 - 2127 (2006).
13. M. Romio, B. Reinbeck, S. Bongardt, S. Hüls, S. Burghoff, J. Schrader, Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am. J. Physiol. Cell Physiol. 301, C530-C539 (2011).
14. B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden, C. E. Müller, International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-An update. Pharmacol. Rev. 63, 1- 34 (2011).
15. G. Haskó, J. Linden, B. Cronstein, P. Pacher, Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7, 759-770 (2008).
16. C. E. Müller, K. A. Jacobson, Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta 1808, 1290-1308 (2011).
17. P. K. Nair, O. C. Marroquin, S. R. Mulukutla, S. Khandhar, V. Gulati, J. T. Schindler, J. S. Lee, Clinical utility of regadenoson for assessing fractional flow reserve. JACC Cardiovasc. Interv. 4, 1085-1092 (2011).
18. A. El-Tayeb, J. Iqbal, A. Behrenswerth, M. Romio, M. Schneider, H. Zimmermann, J. Schrader, C. E. Müller, Nucleoside-5?-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5?-nucleotidase. J. Med. Chem. 52, 7669-7677 (2009).
19. U. Flögel, Z. Ding, H. Hardung, S. Jander, G. Reichmann, C. Jacoby, R. Schubert, J. Schrader, In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 118, 140-148 (2008).
20. H. Tsukamoto, P. Chernogorova, K. Ayata, U. V. Gerlach, A. Rughani, J. W. Ritchey, J. Ganesan, M. Follo, R. Zeiser, L. F. Thompson, M. Idzko, Deficiency of CD73/ecto-5?-nucleotidase in mice enhances acute graft-versus-host disease. Blood 119, 4554-4564 (2012).
21. G. M. Cunha, P. M. Canas, C. S. Melo, J. Hockemeyer, C. E. Muller, C. R. Oliveira, R. A. Cunha, Adenosine A2A receptor blockade prevents memory dysfunction caused by b-amyloid peptides but not by scopolamine or MK-801. Exp. Neurol. 210, 776-781 (2008).
22. P. L. van Lent, A. B. Blom, L. Grevers, A. Sloetjes, W. B. van den Berg, Toll-like receptor 4 induced FcgR expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: Toll-like receptor 4 largely regulates FcgR expression by interleukin 10. Ann. Rheum. Dis. 66, 334-340 (2007).
23. G. Xuzhu, M. Komai-Koma, B. P. Leung, H. S. Howe, C. McSharry, I. B. McInnes, D. Xu, Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann. Rheum. Dis. 71, 129-135 (2012).
24. S. Nakae, A. Nambu, K. Sudo, Y. Iwakura, Suppression of immune induction of collageninduced arthritis in IL-17-deficient mice. J. Immunol. 171, 6173-6177 (2003).
25. K. Varani, M. Padovan, M. Govoni, F. Vincenzi, F. Trotta, P. A. Borea, The role of adenosine receptors in rheumatoid arthritis. Autoimmun. Rev. 10, 61-64 (2010).
26. F. Bönner, N. Borg, S. Burghoff, J. Schrader, Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS One 7, e34730 (2012).
27. D. E. Lukashev, P. T. Smith, C. C. Caldwell, A. Ohta, S. G. Apasov, M. V. Sitkovsky, Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochem. Pharmacol. 65, 2081-2090 (2003).
28. C. M. Lappas, J. M. Rieger, J. Linden, A2A adenosine receptor induction inhibits IFN-γ production in murine CD4+ T cells. J. Immunol. 174, 1073-1080 (2005).
29. K. L. Wallace, J. Linden, Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116, 5010-5020 (2010).
30. V. Savic, V. Stefanovic, N. Ardaillou, R. Ardaillou, Induction of ecto-5?-nucleotidase of rat cultured mesangial cells by interleukin-1β and tumour necrosis factor-a. Immunology 70, 321-326 (1990).
31. N. D. Khoa, M. C. Montesinos, A. B. Reiss, D. Delano, N. Awadallah, B. N. Cronstein, Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells. J. Immunol. 167, 4026-4032 (2001).
32. A. Fortin, D. Harbour, M. Fernandes, P. Borgeat, S. Bourgoin, Differential expression of adenosine receptors in human neutrophils: Up-regulation by specific Th1 cytokines and lipopolysaccharide. J. Leukoc. Biol. 79, 574 -585 (2006).
33. H. K. Eltzschig, P. Carmeliet, Hypoxia and inflammation. N. Engl. J. Med. 364, 656- 665 (2011).
34. P. Yde, B. Mengel, M. H. Jensen, S. Krishna, A. Trusina, Modeling the NF- kb mediated inflammatory response predicts cytokine waves in tissue. BMC Syst. Biol. 5, 115 (2011).
35. J. Zezula, M. Freissmuth, The A2A-adenosine receptor: A GPCR with unique features? Br. J. Pharmacol. 153 (Suppl. 1), S184-S190 (2008).
36. N. D. Khoa, M. Postow, J. Danielsson, B. N. Cronstein, Tumor necrosis factor-a prevents desensitization of G a s-coupled receptors by regulating GRK2 association with the plasma membrane. Mol. Pharmacol. 69, 1311-1319 (2006).
37. W. Schütz, J. Schrader, E. Gerlach, Different sites of adenosine formation in the heart. Am. J. Physiol. 240, H963-H970 (1981).
38. B. Ebner, P. Behm, C. Jacoby, S. Burghoff, B. A. French, J. Schrader, U. Flögel, Early assessment of pulmonary inflammation by 19F MRI in vivo. Circ. Cardiovasc. Imaging 3, 202 -210 (2010).
39. U. Flögel, S. Su, I. Kreideweiss, Z. Ding, L. Galbarz, J. Fu, C. Jacoby, O. Witzke, J. Schrader, Noninvasive detection of graft rejection by in vivo 19F MRI in the early stage. Am. J. Transplant. 11, 235-244 (2011).
40. J. D. Isaacs, Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future. Rheumatology 47, 1461-1468 (2008).
41. M. R. Ehrenstein, J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, C. Mauri, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200, 277-285 (2004).
42. S. Deaglio, K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, V. K. Kuchroo, T. B. Strom, S. C. Robson, Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
43. B. Cronstein, How does methotrexate suppress inflammation? Clin. Exp. Rheumatol. 28, S21-S23 (2010).
44. L. Morabito, M. C. Montesinos, D. M. Schreibman, L. Balter, L. F. Thompson, R. Resta, G. Carlin, M. A. Huie, B. N. Cronstein, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5? -nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101, 295 -300 (1998).
45. M. C. Montesinos, M. Takedachi, L. F. Thompson, T. F. Wilder, P. Fernández, B. N. Cronstein, The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5?-nucleotidase: Findings in a study of ecto-5?- nucleotidase gene-deficient mice. Arthritis Rheum. 56, 1440-1445 (2007).
46. J. Linden, Regulation of leukocyte function by adenosine receptors. Adv. Pharmacol. 61, 95-114 (2011).
47. J. M. Wilson, W. G. Ross, O. N. Agbai, R. Frazier, R. A. Figler, J. Rieger, J. Linden, P. B. Ernst, The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J. Immunol. 182, 4616 -4623 (2009).
48. M. I. Koenders, R. J. Marijnissen, I. Devesa, E. Lubberts, L. A. Joosten, J. Roth, P. L. van Lent, F. A. van de Loo, W. B. van den Berg, Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritis. Arthritis Rheum. 63, 2329-2339 (2011).